SOS
ALBO

Silver Oak Securities’s Albireo Pharma Inc ALBO Stock Holding History

Silver Oak Securities’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-23,795
Closed -$836K – 352
2022
Q1 		$836K Buy
+23,795
New +$697K 0.17% 126

Other funds holding ALBO

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Silver Oak Securities's ALBO Position: Q2 2022 in Review

Silver Oak Securities sold out of Albireo Pharma Inc (ALBO) in Q2 2022, closing a stake of 23,795 shares — an estimated $836K sold.

Silver Oak Securities first reported a position in ALBO in Q1 2022 and held it in 1 quarter. The position peaked at $836K in Q1 2022. 103 funds tracked by Wall St. Rank hold ALBO as of Q2 2022.

  • Silver Oak Securities reported no remaining Albireo Pharma Inc position as of Q2 2022 after selling out during the quarter.
  • Silver Oak Securities sold 23,795 Albireo Pharma Inc shares in Q2 2022, an estimated $836K.
  • Silver Oak Securities first reported a position in Albireo Pharma Inc in Q1 2022 and held it in 1 quarter.
  • Silver Oak Securities's Albireo Pharma Inc position peaked at $836K in Q1 2022.
  • 103 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q2 2022.

Based on Silver Oak Securities's 13F filing for Q2 2022, filed 15 Aug 2022.